← Back to Search

YMCA Class for Non-alcoholic Fatty Liver Disease

N/A

Waitlist Available

Led By Sonal Kumar, MD

Research Sponsored by Weill Medical College of Cornell University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 104 weeks from the start of the study

Awards & highlights

Study Summary

This trial is for men and women who have been diagnosed with NAFLD and will participate in the YMCA's Diabetes Prevention Program.

Eligible Conditions

Non-alcoholic Fatty Liver Disease
Liver Disease
Weight Loss

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 104 weeks from the start of the study

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~104 weeks from the start of the study

This trial's timeline: 3 weeks for screening, Varies for treatment, and 104 weeks from the start of the study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determine if Liver Fat via Fibroscan Controlled Attentuation Pattern score has decreased as a result of YMCA program

Effect of the YMCA's Diabetes Prevention Program on NAFLD

Secondary outcome measures

Measuring the effectiveness of the YMCA Program, as per SF-36 patient-reported questionnaires

Measuring the effectiveness of the YMCA Program, as per each patient's BMI

Measuring the effectiveness of the YMCA Program, as per metabolic blood work that's analyzed

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: YMCA ClassExperimental Treatment1 Intervention

This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

YMCA class

2018

N/A

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

YMCAOTHER

15 Previous Clinical Trials

2,278 Total Patients Enrolled

Weill Medical College of Cornell UniversityLead Sponsor

1,054 Previous Clinical Trials

1,316,568 Total Patients Enrolled

2 Trials studying Non-alcoholic Fatty Liver Disease

53 Patients Enrolled for Non-alcoholic Fatty Liver Disease

Sonal Kumar, MDPrincipal InvestigatorWeill Medical College of Cornell University

1 Previous Clinical Trials

40 Total Patients Enrolled

1 Trials studying Non-alcoholic Fatty Liver Disease

40 Patients Enrolled for Non-alcoholic Fatty Liver Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment for the trial ongoing?

"Based on the research available from clinicaltrials.gov, this trial is no longer seeking participants; it was first publicised on March 1st 2018 and last updated January 26th 2022. Although this study has concluded its recruitment period, 601 other medical trials are actively searching for candidates right now."

Answered by AI

What aims does this clinical experiment hope to attain?

"The primary outcomes of this study, conducted over a period of 104 weeks, will evaluate the effect of YMCA's Diabetes Prevention Program on Non-Alcoholic Fatty Liver Disease (NAFLD). Secondary objectives include assessing program effectiveness in terms of Body Mass Index (BMI) via aggregate body fat percentage and lean/fat mass through dual-energy X-ray absorptiometry scans, as well as identifying correlations between metabolic syndrome symptoms and systemic factors from research-related blood work."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

YMCA Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

2018. "YMCA Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03512184.